⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNKD News
Mannkind Corporation
MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes
globenewswire.com
MNKD
Form 8-K
sec.gov
MNKD
MannKind to Present at Jefferies Global Healthcare Conference
globenewswire.com
MNKD
MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems
globenewswire.com
MNKD
Form 8-K
sec.gov
MNKD
The $59B Quiet Shift Reshaping How Patients Access Care
prnewswire.com
NVO
DNA
HIMS
MNKD
Form 8-K
sec.gov
MNKD
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
MNKD
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
globenewswire.com
MNKD
UTHR
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
globenewswire.com
MNKD